HuGE Literature Finder
Records
1
-
30
| Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC cancer 2023 1 23 (1): 6. Miura Satoru, Koh Yasuhiro, Azuma Koichi, Yoshioka Hiroshige, Koyama Kenichi, Teraoka Shunsuke, Ishii Hidenobu, Kibata Kayoko, Ozawa Yuichi, Tokito Takaaki, Oyanagi Jun, Shimokawa Toshio, Kurata Takayasu, Yamamoto Nobuyuki, Tanaka Hiros |
| Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study. BMC pulmonary medicine 2022 Oct 22 (1): 381. Wei Jingwen, Xiang Jing, Hao Yue, Si Jinfei, Wang Wenxian, Li Fangyin, Song Zheng |
| Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease. Journal of the American Society of Nephrology : JASN 2022 2 33 (5): 985-995. Vlasschaert Caitlyn, McNaughton Amy J M, Chong Michael, Cook Elina K, Hopman Wilma, Kestenbaum Bryan, Robinson-Cohen Cassianne, Garland Jocelyn, Moran Sarah M, Paré Guillaume, Clase Catherine M, Tang Mila, Levin Adeera, Holden Rachel, Rauh Michael J, Lanktree Matthew |
| Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer. The oncologist 2022 3 27 (3): 163-e213. Jian Hong, Wang Kai, Cheng Ying, Ding Lieming, Wang Yang, Shi Zhe, Zhang Ling, Wang Yaolin, Lu Sh |
| First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in oncology 2021 4 11 598265. Wu Qiang, Luo Wuxia, Li Wen, Wang Ting, Huang Lin, Xu Fe |
| Germline mutations and age at onset of lung adenocarcinoma. Cancer 2021 4 127 (15): 2801-2806. Reckamp Karen L, Behrendt Carolyn E, Slavin Thomas P, Gray Stacy W, Castillo Danielle K, Koczywas Marianna, Cristea Mihaela C, Babski Kirsten M, Stearns Donna, Marcum Catherine A, Rodriguez Yenni P, Hass Amie J, Vecchio Mary M, Mora Pamela, Cervantes Aleck E, Sand Sharon R, Mejia Rosa M, Tsou Terrence C, Salgia Ravi, Weitzel Jeffrey |
| NT-proBNP level in stage 3-4 chronic kidney disease and mortality in long-term follow-up: HAPPY study subgroup analysis. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2020 Jul 48 (5): 454-460. ?im?ek Mustafa Aytek, De?ertekin Muzaffer, Türer Cabbar Ayça, Hünük Burak, Aktürk Serkan, Erdo?mu? Siyar, Mutlu Bülent, Kozan Öm |
| Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of clinical medicine 2020 Jun 9 (6): . Nakao Akira, Hiranuma Osamu, Uchino Junji, Sakaguchi Chikara, Araya Tomoyuki, Hiraoka Noriya, Ishizuka Tamotsu, Takeda Takayuki, Kawasaki Masayuki, Goto Yasuhiro, Imai Hisao, Hattori Noboru, Nakatomi Keita, Uramoto Hidetaka, Uryu Kiyoaki, Fukuda Minoru, Uchida Yasuki, Yokoyama Toshihide, Akai Masaya, Mio Tadashi, Nagashima Seiji, Chihara Yusuke, Tamiya Nobuyo, Kaneko Yoshiko, Mouri Takako, Yamada Tadaaki, Yoshimura Kenichi, Fujita Masaki, Takayama Koic |
| Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations. Journal of thoracic disease 2020 May 12 (5): 1895-1902. Kang Hye Seon, Shin Ah Young, Yeo Chang Dong, Park Chan Kwon, Kim Ju Sang, Kim Jin Woo, Kim Seung Joon, Lee Sang Haak, Kim Sung Kyou |
| Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thoracic cancer 2020 Mar . Kishikawa Takayuki, Kasai Takashi, Okada Masahiko, Nakachi Ichiro, Soda Sayo, Arai Ryo, Takigami Ayako, Sata Masafu |
| Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. Clinical colorectal cancer 2020 Mar . Chibaudel Benoist, André Thierry, Tournigand Christophe, Louvet Christophe, Benetkiewicz Magdalena, Larsen Annette K, de Gramont Aime |
| Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. Journal of the Formosan Medical Association = Taiwan yi zhi 2020 1 119 (10): 1506-1513. Chen Chung-Yu, Chen Kuan-Yu, Shih Jin-Yuan, Yu Chong-J |
| Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung cancer (Amsterdam, Netherlands) 2020 10 150 62-69. Garcia-Campelo Rosario, Arrieta Oscar, Massuti Bartomeu, Rodriguez-Abreu Delvys, Granados Ana Laura Ortega, Majem Margarita, Vicente David, Lianes Pilar, Bosch-Barrera Joaquim, Insa Amelia, Dómine Manuel, Reguart Noemí, Guirado María, Sala María Ángeles, Vázquez-Estevez Sergio, Caro Reyes Bernabé, Drozdowskyj Ana, Verdú Ana, Karachaliou Niki, Molina-Vila Miguel Angel, Rosell Rafael, |
| First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. Clinical lung cancer 2020 8 21 (6): 509-519.e1. Zheng Jing, Shen Lisha, Jiang Nan, Zhu Yanping, Wu Lihua, Cao He, Sun Wenjia, Zhou Jianya, Zhou Jianyi |
| Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 5 38 (19): 2187-2196. Kenmotsu Hirotsugu, Yamamoto Nobuyuki, Yamanaka Takeharu, Yoshiya Katsuo, Takahashi Toshiaki, Ueno Tsuyoshi, Goto Koichi, Daga Haruko, Ikeda Norihiko, Sugio Kenji, Seto Takashi, Toyooka Shinichi, Date Hiroshi, Mitsudomi Tetsuya, Okamoto Isamu, Yokoi Kohei, Saka Hideo, Okamoto Hiroaki, Takiguchi Yuichi, Tsuboi Masahi |
| A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung cancer (Amsterdam, Netherlands) 2019 7 134 46-51. Park Ji Soo, Hong Min Hee, Chun You Jin, Kim Hye Ryun, Cho Byoung Ch |
| The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis. Pathology oncology research : POR 2019 6 26 (2): 1137-1143. Zhang Lei, Ren Hong-Wei, Wu Qi-Long, Wu Yan-Juan, Song Xia |
| Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
| Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer chemotherapy and pharmacology 2018 May . Imai Hisao, Minemura Hiroyuki, Sugiyama Tomohide, Yamada Yutaka, Kaira Kyoichi, Kanazawa Kenya, Kasai Takashi, Kaburagi Takayuki, Minato Koichi, |
| Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study. Clinical lung cancer 2018 11 19 (6): 484-492. Xie Hounai, Wang Hui, Xu Lin, Li Meng, Peng Yue, Cai Xianyun, Feng Zhen, Ren Wangang, Peng Zhongm |
| A polymorphism at IGF1 locus is associated with anemia. Oncotarget 2017 Mar . Marini Maria Adelaide, Mannino Gaia Chiara, Fiorentino Teresa Vanessa, Andreozzi Francesco, Perticone Francesco, Sesti Giorg |
| Sickle Cell Trait and Renal Function in Hispanics in the United States: The Northern Manhattan Study. Ethnicity & disease 2017 Jan 27 (1): 11-14. Dueker Nicole D, Della-Morte David, Rundek Tatjana, Sacco Ralph L, Blanton Susan |
| Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. The Korean journal of internal medicine 2016 Nov 31 (6): 1140-1149. Park Sehhoon, Park Seongyeol, Lee Se-Hoon, Suh Beomseok, Keam Bhumsuk, Kim Tae Min, Kim Dong-Wan, Kim Young Whan, Heo Dae Se |
| Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis. Meta gene 2016 Sep 9 110-9. Zhou Mingyi, Yu Ping, Hou Kezuo, Fu Lingyu, Chen Ying, Qu Jinglei, Qu Xiujuan, Liu Yunpeng, Zhang Jingdo |
| Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Oncotarget 2016 May . Zhang Minghui, Guo Hongsheng, Zhao Shu, Wang Yan, Yang Maopeng, Yu Jiawei, Yan Yubo, Wang Y |
| Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. AIDS (London, England) 2016 May . Kheloufi Farid, Bellissant Eric, Cotte Laurent, Poizot-Martin Isabelle, Quaranta Sylvie, Garraffo Rodolphe, Barrail-Tran Aurélie, Renault Alain, Fournier Isabelle, Lacarelle Bruno, Bourlière Marc, Molina Jean-Michel, Solas Caroline, |
| Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
| Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. Antimicrobial agents and chemotherapy 2015 Jun 59 (6): 3257-62. Gutierrez-Valencia Alicia, Ruiz-Valderas Rosa, Ben-Marzouk-Hidalgo Omar J, Torres-Cornejo Almudena, Espinosa Nuria, Castillo-Ferrando Juan R, Viciana Pompeyo, Lopez-Cortes Luis |
| The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Current oncology reports 2014 Jun 16 (6): 390. Yang XiongWen, Yang Ke, Kuang Kang |
| A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 29, 2023
- Content source: